Vol.53 No.S-2 November 2005
Clinical trial of voriconazole in Europe and the United States
Professor of Medicine, Director, San Antonio Center for Medical Mycology, University of Texas Health Science Center,
7703 Floyd Curl Drive, San Antonio, Texas, USA
Abstract
Aspergillus has recently replaced Candida as the primary cause of death due to fungal infection, making it urgent to find drugs with good activity against Aspergillus. The new azole antifungal voriconazole (VRCZ) showed greater effectiveness and tolerability against aspergillosis than the conventional gold standard, Amphotericin B (AMPH). It also improved the survival of invasive aspergillosis patients with unfavorable prognosis. Earlier treatment with VRCZ would be expected to result in even better effectiveness and survival. Empiric treatment with VRCZ is expected to effectively prevent the onset of aspergillosis in high-risk patients.
Key word
voriconazole, aspergillosis, invasive pulmonary aspergillosis, combination therapy, early treatment
Received
July 8, 2005
Accepted
August 22, 2005
Jpn. J. Chemother. 53 (S-2): 24-31, 2005
